Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model

Br J Pharmacol. 2023 May;180(10):1362-1378. doi: 10.1111/bph.16020. Epub 2023 Jan 9.

Abstract

Background and purpose: Opioids are commonly used for the management of cancer-associated pain and chemotherapy-induced diarrhoea. The chemotherapeutic irinotecan (CPT-11) causes severe gastrointestinal (GI) toxicity due to deconjugation of inactive metabolite SN-38 glucuronide (SN-38G) by bacterial β-glucuronidases to the active 7-ethyl-10-hydroxycamptothecin (SN-38). Opioids are known to cause gut microbial dysbiosis, this study evaluated whether CPT-11 anti-tumour efficacy and GI toxicity are exacerbated by opioid co-administration.

Experimental approach: Eight-week-old C57BL/6 male mice were co-administration with CPT-11 ± opioid. 16S rRNA sequencing was used for gut microbiome analysis. LC-MS analyses of plasma and intestinal extracts were performed to investigate the pharmacokinetic profile of CPT-11. Histological analysis and quantitative real-time polymerase chain reaction were used to determine the severity of intestinal tissue damage. Human liver microsome In vitro assay was performed to confirm the effects of opioids on CPT-11 metabolism.

Key results: Gut microbiome analysis showed that morphine treatment induced enrichment of β-glucuronidase-producing bacteria in the intestines of CPT-11-treated mice, resulting in SN-38 accumulation and exacerbation of GI toxicity in the small intestine. Oral administration of both antibiotics and glucuronidase inhibitor protected mice against GI toxicity induced with CPT-11 and morphine co-administration, implicating a microbiome-dependent mechanism. Additionally, morphine and loperamide decreased the plasma concentration of SN-38 and compromised CPT-11 anti-tumour efficacy, this seemed to be microbiome independent.

Conclusion and implications: Gut microbiota play a significant role in opioid and chemotherapeutic agent drug-drug interactions. Inhibition of gut microbial glucuronidase may also prevent adverse GI effects of CPT-11 in patients on opioids.

Keywords: CPT-11; chemotherapy; drug metabolism; gut microbiome; irinotecan; opioids.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / pharmacology
  • Animals
  • Antineoplastic Agents, Phytogenic* / toxicity
  • Bacteria
  • Camptothecin / toxicity
  • Disease Models, Animal
  • Dysbiosis
  • Glucuronidase / metabolism
  • Glucuronidase / pharmacology
  • Humans
  • Irinotecan
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Morphine Derivatives / pharmacology
  • Neoplasms*
  • RNA, Ribosomal, 16S

Substances

  • Irinotecan
  • Analgesics, Opioid
  • RNA, Ribosomal, 16S
  • Antineoplastic Agents, Phytogenic
  • Camptothecin
  • Glucuronidase
  • Morphine Derivatives